SNPX

Synaptogenix (SNPX)

About Synaptogenix (SNPX)

Synaptogenix, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the development of Bryostatin and Platform Drug used for the treatment of Alzheimer’s disease, Fragile X Syndrome or Autism, Multiple Sclerosis, Parkinson’s Disease, Traumatic Brain Injury, and Stroke. The company was founded on October 31, 2012 and is headquartered in New York, NY.

Details

Daily high

$2.79

Daily low

$2.76

Price at open

$2.86

52 Week High

$6.22

52 Week Low

$2.32

Market cap

3.9M

Dividend yield

0.00%

Volume

4,437

Avg. volume

4,893

P/E ratio

-.38

Synaptogenix News